Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EUSA Pharma, a pharmaceutical company, with special focus on oncology, has secured FDA approval for its orphan drug Erwinaze (asparaginase Erwinia chrysanthemi), used to treat acute lymphoblastic leukemia (ALL) in those hypersensitive to E. coli-derived asparaginase.
Subscribe to our email newsletter
Erwinaze is an asparaginase enzyme which depletes asparagine level in the bloodstream. Asparagine helps in cell growth, and its removal from the blood inhibits the growth of cells associated with acute lymphoblastic leukemia.
The approval is backed by clinical studies in 630 ALL patients, which yielded a positive data.
EUSA Pharma Chief Medical Officer Tim Corn said the approval of Erwinaze represents its continued dedication in the field of oncology.